Oncotarget

Research Papers:

Prospects of estrogen receptor β activation in the treatment of castration-resistant prostate cancer

Julia Gehrig, Silke Kaulfuß, Hubertus Jarry, Felix Bremmer, Mark Stettner, Peter Burfeind and Paul Thelen _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:34971-34979. https://doi.org/10.18632/oncotarget.16496

Metrics: PDF 1883 views  |   HTML 2219 views  |   ?  


Abstract

Julia Gehrig1, Silke Kaulfuß1, Hubertus Jarry2, Felix Bremmer3, Mark Stettner4, Peter Burfeind1 and Paul Thelen5

1Institute of Human Genetics, University Medical Center Goettingen, Germany

2Department of Experimental Endocrinology, University Medical Center Goettingen, Germany

3Institute of Pathology, University Medical Center Goettingen, Germany

4Department of Neurology, University of Essen, Germany

5Department of Urology, University Medical Center Goettingen, Germany

Correspondence to:

Paul Thelen, email: pthelen@gwdg.de

Keywords: ADT, estrogen receptor β, 8β-VE2, androgen receptor, therapy resistance

Received: July 20, 2016     Accepted: March 08, 2017     Published: March 23, 2017

ABSTRACT

Advanced prostate cancer can develop into castration-resistant prostate cancer (CRPC). This process is mediated either by intratumoral ligand synthesis or by mutations or aberrations of the androgen receptor (AR) or its cofactors. To date, no curative therapy for CRPC is available, as AR-targeted therapies eventually result in the development of resistance. The human prostate cancer cell line VCaP (vertebral cancer of the prostate) overexpresses AR and its splice variants (ARVs) as a mechanism of resistance to androgen-deprivation therapy (ADT) of external and intratumoral origin. In the present study, we demonstrate that stimulating estrogen receptor β activity with the specific agonist 8β-VE2 in VCaP cells in successive stages of ADT induced a time- and dose-dependent decrease in cell survival and an increase in apoptosis. Furthermore, 8β-VE2 treatment reduced the overexpression of the AR as well as ARVs in VCaP cells under maximum ADT. Our results indicate that decreased survival of the androgen-dependent CRPC cells employing apoptosis together with the regulative effect on AR expression could have beneficial effects over current AR-targeting therapies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16496